Skip to content

Re-evaluation of Zhuifengtougu capsule in the treatment of scapulohumeral periarthritis

Re-evaluation of Zhuifengtougu capsule in the treatment of scapulohumeral periarthritis

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000028808
Enrollment
Unknown
Registered
2020-01-04
Start date
2020-01-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periarthritis of shoulder

Interventions

Sponsors

Temporarily not sure
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18-75 years; (2) meet the diagnostic criteria of periarthritis of shoulder.

Exclusion criteria

Exclusion criteria: (1) Tuberculosis, tumor of shoulder joint or unhealed fracture of shoulder; (2) bleeding tendency, gastrointestinal bleeding or other chronic bleeding disease within one month; (3) allergic constitution or allergic to known ingredients of the medicine; (4) pregnant and lactating women; (5) those with serious diseases such as heart, lung, liver, kidney, hematopoietic system and immune system.

Design outcomes

Primary

MeasureTime frame
Scores of symptoms and signs related to periarthritis of shoulder;

Secondary

MeasureTime frame
Vas Quantitative Score;Melle rating scale integral;Quality of life assessment;

Countries

China

Contacts

Public ContactHe Yanlin
767567825@qq.com+86 15084974669

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026